Driver tyrosine kinase mutations are rare in sarcomas and patterns of tyrosine phosphorylation are poorly understood. To better understand the signaling pathways active in sarcoma, we examined global tyrosine phosphorylation in sarcoma cell lines and human tumor samples. Anti-phospho-tyrosine antibodies were used to purify tyrosine-phosphorylated peptides, which were then identified using liquid chromatography and tandem mass spectrometry. The findings were validated using RNA interference, rescue, and small molecule tyrosine kinase inhibitors. We identified 1,936 unique tyrosine phosphorylated peptides, corresponding to 844 unique phospho-tyrosine proteins. In sarcoma cells alone, peptides corresponding to 39 tyrosine kinases were found. 
INTRODUCTION
Sarcomas are rare and diverse malignancies that arise from mesenchymal derived connective tissues.
Advances in understanding the genetic nature of cancer have lead to the development of new treatment options for sarcoma. For example, gastrointestinal stromal tumors (GIST) that harbor activating mutations in orally available multi-targeted tyrosine kinase inhibitor of VEGFR, PDGFR, c-KIT and FLT-3 kinases (2) . The example of GIST is encouraging and hopefully will prove to be a model for developing new agents for the other sarcoma subtypes. Furthermore, many sarcomas harbor balanced translocations that result in unique fusion proteins that have been shown to deregulate various kinases (3) .
Despite advances in GIST, effective treatment options for metastatic soft tissue sarcomas and
osteosarcoma have yet to be demonstrated. In addition to c-KIT in GIST, a number of other tyrosine kinases (TK) have been suggested to be important as drivers of oncogenesis in sarcoma (Reviewed in (4) ). These include platelet-derived growth factors (PDGFs) and their tyrosine kinase receptors (PDGFRs), the epidermal growth factor receptor (EGFR), the human epidermal growth factor receptor-2 (HER-2), vascular endothelial growth factor (VEGF) and its receptors, and the insulin-like growth factor receptor (IGF1R). Despite encouraging preclinical studies and studies demonstrating receptor expression in sarcoma tumor specimens, activity of tyrosine kinase inhibitors (TKI) in patients with advanced sarcoma has been limited. For example, phase II studies using EGFR TKI in sarcoma have disappointingly demonstrated no clinical activity (5) . There are a number of potential reasons for lack of efficacy of TKI in sarcoma. These include not enriching for patients whose tumor depends on the particular tyrosine kinase for growth/survival and a lack of assays that detect an activated tyrosine kinase that predicts drug sensitivity. In addition, it is possible that other driver tyrosine kinases are co-expressed in sarcoma cells and maintain signaling despite inhibition of one particular TK (6) . Thus, for true efficacy, combinations of different TKI may be required.
One technique that may be helpful to identifying tumor cells dependent on kinases for growth and/or survival, as well as charting the landscape of activated tyrosine kinases in tumor cells, is mass spectrometry (MS)-based phosphoproteomics (7) . The technique has been limited since phosphorylated tyrosine residues (pY) represent only 0.5% of the total phosphoamino acids within a cell (8) . However, more sensitive mass spectrometers have been coupled with anti-pY antibodies to purify either proteins or enzymatically-digested peptides for analysis. This approach has been used to characterize protein networks and pathways Author Manuscript Published OnlineFirst on March 29, 2012 ; DOI: 10.1158/0008-5472. downstream of oncogenic HER2, BCR-ABL, and SRC (9) (10) (11) (12) . These methods can also be used to identify novel tyrosine phosphorylation sites and identify oncogenic proteins resulting from activating mutations in protein tyrosine kinases (10, 11, 13, 14) . The data can then be used in either expert literature curation or machine learning techniques to synthesize network models that can be further evaluated (9) . The methodologies can be coupled with TKI or other compounds to further understand their effect on protein networks. Identification of critical tyrosine kinase proteins in an important oncogenic network may also suggest 'druggable' targets that can be entered into therapeutic discovery research.
We hypothesized that a phosphoproteomics strategy in sarcoma cells and tumors could (i) identify tyrosine kinases and substrate proteins important in the malignant process, (ii) define functional tyrosine kinases driving sarcoma cell growth and survival, (iii) suggest studies in human tumors for activated kinases and kinase substrates. We used multiple validation strategies, including RNA interference, use of small molecule tyrosine kinase inhbitors, and rescue strategies to define MET, PDGFR, SRC, and IGF1R/INSR signaling as important in individual sarcoma cell lines. Finally, we conducted pilot experiments using primary explant models of sarcoma tissues to explore tyrosine kinase signaling in human tumor tissues.
Research. purchased from EMD (Gibbstown, NJ). ZD6474 (vandetanib) was purchased by Huskerchem Inc. (Riverside, CA). Viability was assessed after 72 hours treatment using MTT assays (MTT, Roche). The IC 50 was defined as the drug concentration that induced 50% cell viability in comparison with DMSO controls and was calculated by non-linear regression analysis (Prism, GraphPad 5.0).
Phospho-RTK Array Assay
42 human receptor tyrosine kinases phosphorylation level determination in sarcoma cell lines was performed using the Proteome Profiler Array Kit (R&D Systems, Minneapolis, MN).
Protein Expression Analysis
Western blotting was performed as previously described (12 
Transfection of Small Interfering RNA
The small interfering RNAs (siRNA) ON-TARGET plus SMART pool were used along with ON-TARGET plus Non-targeting pool as a negative control obtained from Dharmacon (Chicago, IL). Transfection was performed with Lipofectamine TM RNAiMAX from Invitrogen (Carlsbad, CA) using reverse transfection procedure as recommended by manufacturer.
Rescue experiments with gatekeeper mutant version of tyrosine kinases
Rescue experiments were performed as previously described (12 
RESULTS

Expression Profiling of tyrosine phosphorylated peptides in sarcoma cell lines identifies novel tyrosine kinases
We employed phosphotyrosine (pY) peptide immunoprecipitation followed by liquid chromatography coupled to tandem mass spectrometry peptide sequencing (LC-MS/MS) to identify pY proteins in a collection of sarcoma cell lines. Briefly, pY containing peptides are isolated directly from protease-digested cellular protein extracts with a pY-specific antibody and are identified by tandem MS peptide sequencing (11) . Applying this approach to several cell systems, including cancer cell lines, has demonstrated that it can identify activated protein kinases and their phosphorylated substrates without prior knowledge of the actived signaling networks (12) . Ten sarcoma cell lines originating from distinct histologies were characterized. These include osteosarcoma (MNNG, U2OS, MG63, and Saos2), rhabdomyosarcoma (RD18, A204), leiomyosarcoma (SK-LMS1), fibrosarcoma (HT1080), and Ewing's sarcoma (RD-ES, A673). Tyrosine-phosphorylated peptides were purified and analyzed using nanoflow LC coupled to a hybrid linear ion trap mass spectrometer (LTQ-Orbitrap).
We identified 3878 (1936 unique) tyrosine-phosphorylated peptides corresponding to 844 unique phospho-tyrosine proteins (Supplemental Table1and 2). Of these proteins, 39 represent tyrosine kinases (Figure1A and Table 1 ). Therefore, of the 99 tyrosine kinases present in the human genome, we identified peptides corresponding to nearly 40% of the tyrosine kinome (16) . Some peptides correspond to known sites of autoactivation (autophosphorylation) suggesting that the kinase is active, while other peptides correspond to sites important in protein-protein interactions, enzymatic activity or of unknown function. Importantly, we identify numerous tyrosine kinases that can be important in signaling transduction in human sarcomas, could drive the natural progression of sarcoma, and could be targeted by small molecule inhibitors to alter that progression. A number of receptor tyrosine kinases were identified including EGFR, multiple Ephrin receptors, multiple FGFR receptors, IGF1R, KIT, MET, and PDGFRα ( Figure 1B phosphorylation were also identified. We carried out confirmatory assays using either RTK arrays or western blotting for a subset of these targets ( Figure 2A and B and Supplemental Figure1A-C). Phosphorylation of PDGFRα was abundant in A204 cells, while higher levels of IGF1R were more prominent in Saos2 and RD-ES cells (Figure 2A ). MET phosphorylation was abundant in MNNG and Saos2 cells and to a lesser extent in U2OS, MG63, SK-LMS1, and H1080 ( Figure 2B ). PDGFRα protein expression was more abundant in A204 and MG63 cells. Overall, these results were consistent with observations from the pY mass spectrometry data.
Effects of tyrosine kinase inhibitors on sarcoma cell line proliferation
Which, if any, of the roughly 40 TKs we identified in tumor cell lines act as driver kinases to regulate tumor cell growth and survival? This is important to help prioritize which targets to examine further in human specimens. For example, some TK may be expressed and be signaling, yet are redundant given the coexpression of other tyrosine kinases. To help investigate this further, we screened the same sarcoma cell lines against inhibitors of EGFR (erlotinib), JAK (P6), FGFR (SU5402), MET (PHA665752), IGF1R (OSI868), RET (ZD6474), PDGFR (imatinib and dasatinib), and SRC (dasatinib) (17, 18) . These compounds were selected based on the tyrosine kinases observed in the mass spectrometry data to gain good coverage of kinases and identify sensitive cells for further validation experiments. We also used results of chemical proteomics reports that more accurately map targets of these kinases and could point to further validation studies (17, (19) (20) (21) (22) (23) .
These data are shown in Table 2 and suggest that some kinases may in fact be drivers of sarcoma cell growth. 
Identification of sarcoma cells dependent on PDGFR Signaling
We noted that the A204 rhabdomyosarcoma cell line had highly abundant pY peptides corresponding to PDGFRα . Validation experiments with RTK array confirmed tyrosine phosphorylated PDGFRα and western blotting showed overexpression of PDGFRα compared to other cell lines studied (see Figure 2A and B). We find that A204 cells are very sensitive to both dasatinib and imatinib, both of which can inhibit PDGFRα kinase activity (17, 18) . A closer examination of the data presented in Table 1 finds that A204 expressed abundant levels of pY peptides corresponding to PDGFRα, a known target of imatinib/dasatinib, while no such PDGFRα pY peptides were found in A673 or RD18 cells which are resistant to both dasatinib and imatinib. For these reasons, we believed that PDGFRα may be an important target in some rhabdomyosarcoma cells and tumors.
Next, we examined downstream signaling in A204 cells. We find that both dasatinib and imatinib inhibit the AKT pathway and induce apoptosis (PARP cleavage) as well as cell cycle arrest (p27 elevation). No obvious changes were observed in ERK phosphorylation and erlotinib had no effects ( Figure 3A ). We engineered A204 cells to express a mutant form of PDGFRα expressing a gatekeeper mutation that prevents tyrosine kinase inhibitor binding to the ATP binding pocket (12) . As shown in Figure 3B , cells expressing this mutant form of PDGFRα were rescued from the effects of dasatinib compared to cells expressing wildtype PDGFRα ( Figure 3B ). We also transfected A204 cells with siRNA against PDGFRα and found significant effects of cell viability ( Figure 3C ). Target inhibition using siRNA was confirmed with western blotting (Supplemental Figure 2 A) . We attempted to determine the mechanism of PDGFRα overexpression and drug sensitivity in the A204 cells. We found no evidence of PDGFRα gene amplification nor did we find evidence of gene mutation (data not shown). In addition, we found no evidence of PAX3:FKHR fusion in these cells which has been reported to drive overexpression of PDGFRα. During the course of our work it was discovered that A204 cells secrete abundant amounts of PDGF that producing autocrine stimulation of PDGFRα (24) .
Research. Using the same antibody used in western blotting experiments and using A204 as a positive control, we established an immunohistochemistry assay to assay PDGFRα in rhabdomyosarcoma tumors obtained from patients. Of 23 specimens, three had 2+ to 3+ staining for PDGFRα and were counted as positive (3/23, 13%) (Figures 3D and Supplemental Table 3 ); two had focal or weak staining (1+) and were counted as negative with the remainders (19/23, 87%). Two of 3 cases are primary tumors and the other was a brain metastasis.
The metastatic lesion had duplicate blocks which were both positive for PDGFRα; however, multiple blocks from other metastatic sites of the same case (lung and subcutaneous) were negative for PDGFRα indicating heterogeneity of the tumor. Primary tumor was not available from this case. Collectively, our MS data and tumor data along with data from other groups suggest suggested PDGFRα as a potential target that is overexpressed in a small group of rhabdomyosarcoma tumors. (25, 26) 
Identification of sarcoma cells dependent on MET Signaling
We identified pY peptides corresponding to MET in 7 of the10 cells with higher spectral counts (a semiquantitative measure of peptide abundance) in MNNG, SK-LMS1, and Saos2 cells. We identified MNNG cells as being sensitive to PHA665752, an inhibitor of MET, while the other cells were largely resistant (IC 50 > 1uM) (17, 18) PHA resulted in strong inhibition of pAKT and pERK in MNNG cells, while no effects were observed using erlotinib as a negative control ( Figure 4A , top panel). PHA resulted in increased PARP cleavage and increased p27 levels ( Figure 4A , middle panel), suggestive of cell apoptosis and cell cycle arrest, respectively.
MET siRNA had strong effects on cell viability in these cells while siRNA against EGFR had no effects ( Figure   4A , bottom panel, and Supplemental Figure 2 B). These results together suggest MET is a driver kinase responsible for cell growth and survival in this particular cell line. Interestingly, the MNNG cells are known to harbor a gene fusion between TPR and MET leading to constitutive MET signaling and transformation (27) . Figure 2C) . In addition to these RNAi experiments, we also examined the effect of another IGF1R/INSR inhibitor BMS-754807 (28). RD-ES cells exhibited the highest sensitivity to this compound compared with the other 9 sarcoma cell lines (Supplemental Figure 3A and B) and we observed similar effects of BMS-754807 compared to OSI868 on RD-ES cells (Supplemental Figure 3C) . Overall, our results are consistent with preclinical and, more recently, clinical trial data suggesting subsets of Ewing's sarcoma cells can be sensitive to IGF1R/INSR signaling (29) (30) (31) (32) .
Identification of sarcoma cells dependent on SRC Signaling
Saos2 cells were identified to be sensitive to dasatinib and had multiple pY peptides corresponding to known targets of dasatinib (SRC family kinases (SFK), Ephrin receptors, ABL, etc). Dasatinib had minimal effects on downstream pAKT with some modest effects on pERK ( Figure 4C, top panel) . It also had minimal effects on PARP cleavage, yet had effects on p27 although similar to those observed with erlotinib ( Figure 4C , middle panel). We did not examine imatinib as the cells were highly resistant. We attempted to use siRNA for SFK and found no effects on cell viability despite good target inhibition ( Figure 4C , bottom panel and Supplemental Figure 2D ). This is not particularly surprising, since a great degree of redundancy exists for SFK signaling. To address this, we next engineered Saos2 cells to express drug resistant alleles of tyrosine 
kinases targeted by dasatinib. Here we expressed wildtype and mutant (drug resistant gatekeeper mutant) forms of 11 dasatinib targets in Saos2 cells and then examined for their effect on dasatinib sensitivity. We specifically examined c-SRC, FYN , EphB1, EphA2, EphA3, DDR1, DDR2, ACK1, PDGFRα, PDGFRβ, and ABL1 ( Figure 4D) . A number of important conclusions are derived from this experiment. First, we do in fact find compensation by alternative SFK, in particular both c-SRC and FYN drug resistant alleles can rescue cells from dasatinib. Second, we found no effect of Ephrins or other dasatinib targets on cell sensitivity. These new data show that dasatinib effects result from SFK inhibition. From these experiments, we conclude that SFK are important drivers of cell growth in Saos2 cells through downstream signaling pathways independent of AKT and ERK.
Phosphotyrosine profiling of human sarcoma tissues
We carried out experiments using LC-MS/MS and phosphopeptide enrichment in snap frozen human sarcoma specimens by employing primary explant models of sarcoma (15) . In these studies, tumor tissue taken directly from patients is implanted into mice and grown as xenografts. These systems are thought to better recapitulate human tumors and are amenable to signaling studies as the excision from mice is rapid and human surgery variables (time of operation, arterial ligations, time to freezing) are mitigated. Tumors included liposarcoma, small round blue tumor, and malignant peripheral nerve sheath tumor histology (Supplemental Table 4 ). We observed comparable amounts of tyrosine phosphorylation in these tumors compared to cell lines indicating retention of tyrosine phosphorylation in these tumor models ( Figure 5A ). Overall, in these three tumor samples, we observed 220 unique pY peptides corresponding to 170 unique proteins (Supplemental Table 2 
DISCUSSION
Phosphotyrosine profiling using affinity capture and LC-MS/MS is a powerful tool for elucidating signaling mechanisms in cancer and monitoring changes during tyrosine kinase inhibitor treatment (33) .
Tyrosine kinases play an important role in controlling hallmarks of cancer and have a proven track record as druggable targets for the treatment of cancer (34) . Screens for tyrosine kinase signaling using anti-phosphotyrosine antibodies to purify tyrosine phosphorylated peptides with identification using LC-MS/MS have identified novel tyrosine kinases that drive cancer cell growth, including ALK and PDGFR in lung cancer cell lines and JAK in leukemia (35, 36) . However, interpretation of these data sets can be difficult and identifying driver kinases can be problematic. Combining genomic or proteomic screens with functional screens has the ability to provide additional evidence for a particular target's importance in cancer signaling. The main goal of the phosphotyrosine MS experiments reported here was to produce a landscape of tyrosine phosphorylated proteins and tyrosine kinases prioritized for subsequent functional validation. We carried out this analysis using Ten sarcoma cell pellets were lysed and phosphopeptides were purified and identified using phosphopeptide Immunoprecipitation and LC-MS/MS. pY sites associated with the corresponding tyrosine kinases were summed and total spectral counts from one biological sample and two MS/MS runs are listed. A204  MG63  A673  RD-ES  Saos2  U2OS  MNNG  RD18  HT1080  Tumor 1  Tumor 2  Tumor 3  SK-LMS1   A204  MG63  A673  RD-ES  Saos2  U2OS  MNNG  RD18  HT1080  Tumor 1  Tumor 2  Tumor 3  SK-LMS1   A204  MG63  A673  RD-ES  Saos2  U2OS  MNNG  RD18  HT1080  Tumor 1  Tumor 2  Tumor 3 
